We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Baxter International Now
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) has been on a healthy growth trajectory, of late. Positive tidings on the regulatory front and strategic acquisitions have been providing the company with a competitive edge in MedTech. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
Baxter International has outperformed the industry in the past year. The stock has gained 29.9%, outperforming the S&P 500’s 15.9% gain and the broader industry’s 16.2%.
The stock has a market cap of $35.29 billion. The company’s next five-year earnings growth rate is also favorable at 12.9% compared with the 9.9% increase of the S&P 500.
The company has a positive earnings surprise of 10.3% for the last four quarters. Also, it has a long-term expected earnings growth rate of 12.5%.
Baxter International has an impressive Growth Style Score of B as well. Our Growth Style Score highlights all the vital metrics of a company’s financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B, when combined with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold), offer the best investment opportunities.
Let’s find out whether the recent positive trend is a sustainable one.
Strategic Acquisition
The market is upbeat about the company’s recent acquisition of the two hemostat and sealant products, RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant, from Mallinckrodt plc.
Solid Guidance
For 2018, Baxter estimates sales growth of approximately 6-7% at constant currency. Adjusted earnings for the full year are expected in the band of $2.72-$2.80 per share.
Solid Estimate Revision Trend
The company’s estimate revision trend for the current year has been positive. In the past couple of months, 9 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 2.9% to $2.78 during the same time frame.
Positive Regulatory tidings
The market is also encouraged to note that Baxter International received the FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
athenahealth is another Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Here's Why You Should Invest in Baxter International Now
Baxter International Inc. (BAX - Free Report) has been on a healthy growth trajectory, of late. Positive tidings on the regulatory front and strategic acquisitions have been providing the company with a competitive edge in MedTech. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
Baxter International has outperformed the industry in the past year. The stock has gained 29.9%, outperforming the S&P 500’s 15.9% gain and the broader industry’s 16.2%.
The stock has a market cap of $35.29 billion. The company’s next five-year earnings growth rate is also favorable at 12.9% compared with the 9.9% increase of the S&P 500.
The company has a positive earnings surprise of 10.3% for the last four quarters. Also, it has a long-term expected earnings growth rate of 12.5%.
Baxter International has an impressive Growth Style Score of B as well. Our Growth Style Score highlights all the vital metrics of a company’s financials to obtain a clearer picture of the quality and sustainability of its growth. Our research shows that stocks with Style Scores of A or B, when combined with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold), offer the best investment opportunities.
Let’s find out whether the recent positive trend is a sustainable one.
Strategic Acquisition
The market is upbeat about the company’s recent acquisition of the two hemostat and sealant products, RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant, from Mallinckrodt plc.
Solid Guidance
For 2018, Baxter estimates sales growth of approximately 6-7% at constant currency. Adjusted earnings for the full year are expected in the band of $2.72-$2.80 per share.
Solid Estimate Revision Trend
The company’s estimate revision trend for the current year has been positive. In the past couple of months, 9 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 2.9% to $2.78 during the same time frame.
Positive Regulatory tidings
The market is also encouraged to note that Baxter International received the FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The company has a long-term expected earnings growth rate of 20%.
athenahealth is another Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>